No new safety signals appeared while patients were on therapy in ENESTop1

Hematologic AEs occurring on TKI therapy during TFR reported in ENESTop

Musculoskeletal pain–related events were observed in 42.1% of patients after stopping treatment vs 14.3% before stopping treatment1

  • Patients experienced musculoskeletal symptoms more frequently than before treatment discontinuation (eg, myalgia, pain in extremity, arthralgia, bone pain, spinal pain, or musculoskeletal pain)1
  • Among musculoskeletal events reported in the TFR phase, most were low grade and occurred during the first 6 months1

Nonhematologic AEs occurring on TKI therapy during TFR reported in ENESTop

aLipid metabolism events were not reported.2
bIncludes the following AEs: edema peripheral (n=3), eyelid edema (n=2), face edema (n=2), swelling face (n=1), and weight increased (n=6). Patients could have had more than 1 AE.2
cIncludes the following AEs: musculoskeletal pain, myalgia, pain in extremity, arthralgia, bone pain, and spinal pain.2
dIncludes only AEs reported as “musculoskeletal pain”; does not include other AE types in the musculoskeletal pain grouping.2

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ELN, European LeukemiaNet; TFR, treatment-free remission; NR, not reported.

  1. Hughes TP, et al. ENESTop Study. ASCO; June 3-7, 2016; Chicago, Illinois. Poster 7054.
  2. Steegmann JL et al. Leukemia. 2016;30(8):1648-1671.